Disease-specific haptoglobin-β chain N-glycosylation as biomarker to differentiate non-small cell lung cancer from benign lung diseases
Disease-specific haptoglobin-β chain N-glycosylation as biomarker to differentiate non-small cell lung cancer from benign lung diseases
复制标题
疾病特异性触珠蛋白-β链 N-糖基化作为区分非小细胞肺癌与良性肺部疾病的生物标志物
DOI：
10.7150/jca.32690
复制
发表时间：
2019-01-01
影响因子：
3.9
通讯作者：
Li, Zhili
中科院分区：
文献类型：
--
作者：
Chen, Tianjing;He, Chengyan;Li, Zhili
背景：结合珠蛋白-βN-糖基化与病理状态的关系已引起越来越多的关注。材料与方法：本研究从300例良性肺部疾病(BLD)和300例非小细胞肺癌(NSCLC)患者的血清免疫炎症相关蛋白复合体(IIRPC)中分离出疾病特异性结合珠蛋白-β(DSHp-β)。用基质辅助激光解吸电离-傅里叶变换离子回旋共振质谱仪(MALDI-FTICR MS)分析DSHp-β胰酶解物中的糖肽。统计分析表明，在BLD和NSCLC患者之间，DSHp-β的唾液酸化发生了显著的变化。年龄和性别匹配的参与者被随机分为训练组和验证组。受试者工作特征(ROC)分析表明，Asn207/211位点糖肽水平比值(G2G3/G2G3S4)具有鉴别非小细胞肺癌和非小细胞肺癌的潜力，其灵敏度为74.4%，特异度为82.8%，曲线下面积(AUC)为0.805。结论：DSHp-β糖基化可用于鉴别非小细胞肺癌和非小细胞肺癌，诊断准确率较高。
Background: The association of pathological states with N-glycosylation of haptoglobin-beta has attracted increasing attention.Materials & Methods: In the present study, disease-specific haptoglobin-beta (DSHp-beta) was separated from serum immunoinflammation-related protein complexes (IIRPCs) of 600 participants including 300 patients with benign lung diseases (BLDs) and 300 patients with non-small cell lung cancer (NSCLC). The enriched glycopeptides of the tryptic digests of the DSHp-beta were analyzed using matrix assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR MS).Results: 20 of glycopeptides were detected for each sample. The statistical analysis has indicated that significant changes in the sialylation of DSHp-beta between BLDs and NSCLC patients were observed. The ageand sex-matched participants were randomly clarified into the training set and the validation set. Receiver operating characteristic (ROC) analysis has revealed that the level ratio of glycopeptides (G2G3/G2G3S4) at the sites of Asn207/211 has potential capability to distinguish BLDs from NSCLC, with the sensitivity of 74.4%, the specificity of 82.8%, and the area under curve (AUC) of 0.805.Conclusion: The glycosylation of DSHp-beta can distinguish NSCLC from BLDs with high diagnostic accuracy compared with current clinical available serum markers.